FDA approves Ilumya for psoriatic arthritis treatment

The FDA has expanded the use of a psoriasis biologic, ILUMYA (tildrakizumab-asmn), to treat the joint inflammation that accompanies the skin disease. The decision adds a new option for adults with active psoriatic arthritis, a condition that can affect joints, the spine, and tendon attachment sites.

Approval based on late-stage trial results

Regulators relied on two phase-III studies, INSPIRE-1 and INSPIRE-2, that measured improvement in joint symptoms after 24 weeks. In the first trial, 61% of participants receiving the drug achieved at least a 20% reduction in joint pain, versus 35% on placebo.

The second study reported similar outcomes, with 64% of treated patients reaching the same benchmark compared with 33% of those given a dummy injection. Benefits emerged as early as week 8 and persisted through the study’s endpoint.

Beyond joint swelling, the trials showed reductions in enthesitis, inflammation where tendons attach to bone, and in dactylitis, the swelling of whole fingers or toes. These secondary improvements support the drug’s broader anti-inflammatory profile.

How the medication is administered

Patients receive a 100-mg injection administered by a health-care professional. The regimen starts with two doses four weeks apart, followed by a maintenance dose every 12 weeks. This schedule mirrors the product’s label for skin disease.

Read Also: Priceline partners with Australian Diamonds netball team

The therapy targets interleukin-23, a protein that drives the immune response in both psoriasis and psoriatic arthritis. According to Sun Pharma, the manufacturer, it is the only IL-23 inhibitor for joint disease delivered exclusively in a provider-controlled setting.

Safety findings aligned with previous experience in skin treatment. No new adverse signals emerged, though the drug may raise infection risk. Patients are screened for tuberculosis before initiation, and the most common side effects, reported in at least 3% of participants, were upper-respiratory infections and COVID-19.

Implications for patients and clinicians

“Psoriatic arthritis is a complex and chronic disease. As clinicians, we need a range of therapeutic options that allow us to individualize care based on each patient’s symptoms and treatment goals,” said Seattle rheumatologist Philip Mease, MD, director of rheumatology research at Swedish Medical Center.

Dermatology editor Christopher Bunick, MD, PhD noted that managing joint involvement is a core part of skin-focused care. He emphasized that the approval broadens the targeted therapies available to patients with significant joint disease.

Patients experiencing stiffness or swelling should discuss these symptoms with their dermatologist, as early recognition can lead to timely treatment. The expanded label provides a pathway for combined skin-and-joint therapy under a single biologic regimen.